Ian T. Clark Sells 6,672 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Ian T. Clark sold 6,672 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total transaction of $322,791.36. Following the transaction, the director now owns 9,851 shares of the company's stock, valued at $476,591.38. This trade represents a 40.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Guardant Health Trading Down 2.8%

Shares of Guardant Health stock traded down $1.43 during trading on Friday, hitting $49.14. The stock had a trading volume of 2,161,505 shares, compared to its average volume of 2,138,716. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of -14.50 and a beta of 1.37. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92. The business's 50-day moving average is $44.45 and its 200 day moving average is $42.05.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. Guardant Health had a negative net margin of 53.82% and a negative return on equity of 1,200.44%. The company's revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.46) earnings per share. As a group, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Hedge Funds Weigh In On Guardant Health

Institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp increased its stake in shares of Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after purchasing an additional 929 shares in the last quarter. Rhumbline Advisers increased its position in shares of Guardant Health by 2.2% during the fourth quarter. Rhumbline Advisers now owns 167,230 shares of the company's stock valued at $5,109,000 after acquiring an additional 3,529 shares in the last quarter. D.A. Davidson & CO. increased its position in shares of Guardant Health by 72.1% during the fourth quarter. D.A. Davidson & CO. now owns 42,380 shares of the company's stock valued at $1,295,000 after acquiring an additional 17,755 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Guardant Health by 6.6% during the fourth quarter. Handelsbanken Fonder AB now owns 28,941 shares of the company's stock valued at $884,000 after acquiring an additional 1,800 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd increased its position in shares of Guardant Health by 15.6% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 13,799 shares of the company's stock valued at $422,000 after acquiring an additional 1,863 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GH has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Scotiabank restated an "outperform" rating on shares of Guardant Health in a report on Monday, May 5th. Canaccord Genuity Group increased their price objective on Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. increased their price objective on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, The Goldman Sachs Group increased their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Twenty-one research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $53.76.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.